Index RUT
P/E -
EPS (ttm) -1.02
Insider Own 4.63%
Shs Outstand 40.97M
Perf Week 1.26%
Market Cap 391.45M
Forward P/E -
EPS next Y -0.23
Insider Trans -0.22%
Shs Float 38.73M
Perf Month -12.84%
Enterprise Value 351.09M
PEG -
EPS next Q -0.12
Inst Own 89.58%
Short Float 6.56%
Perf Quarter 3.54%
Income -41.39M
P/S 1.38
EPS this Y 27.09%
Inst Trans 11.25%
Short Ratio 5.06
Perf Half Y 6.17%
Sales 283.32M
P/B 2.12
EPS next Y 18.70%
ROA -13.57%
Short Interest 2.54M
Perf YTD 5.24%
Book/sh 4.54
P/C 8.75
EPS next 5Y -
ROE -20.46%
52W High 13.50 -28.59%
Perf Year 73.38%
Cash/sh 1.10
P/FCF -
EPS past 3/5Y -77.33% -
ROIC -21.97%
52W Low 5.47 76.23%
Perf 3Y -50.67%
Dividend Est. -
EV/EBITDA 638.35
Sales past 3/5Y 1.46% 2.35%
Gross Margin 50.72%
Volatility 4.89% 4.27%
Perf 5Y -4.65%
Dividend TTM -
EV/Sales 1.24
EPS Y/Y TTM -188.57%
Oper. Margin -9.26%
ATR (14) 0.46
Perf 10Y -41.22%
Dividend Ex-Date -
Quick Ratio 1.40
Sales Y/Y TTM -12.56%
Profit Margin -14.61%
RSI (14) 45.72
Recom 1.00
Dividend Gr. 3/5Y - -
Current Ratio 2.21
EPS Q/Q 97.69%
SMA20 -4.17%
Beta 0.68
Target Price 15.67
Payout -
Debt/Eq 0.02
Sales Q/Q -4.23%
SMA50 -2.06%
Rel Volume 0.98
Prev Close 9.18
Employees 748
LT Debt/Eq 0.01
Earnings Jul 15 BMO
SMA200 5.63%
Avg Volume 501.60K
Price 9.64
IPO May 27, 2004
Option/Short Yes / Yes
EPS/Sales Surpr. 38.46% 2.43%
Trades
Volume 489,182
Change 5.01%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-05-24 Upgrade
Oppenheimer
Perform → Outperform
$12
Sep-25-23 Initiated
H.C. Wainwright
Buy
$19
Apr-17-23 Downgrade
Raymond James
Strong Buy → Outperform
$14 → $13
Oct-15-21 Upgrade
Canaccord Genuity
Hold → Buy
$28 → $37
Aug-20-21 Initiated
Oppenheimer
Perform
Nov-25-20 Upgrade
Raymond James
Mkt Perform → Strong Buy
$18
Apr-08-20 Downgrade
KeyBanc Capital Markets
Overweight → Sector Weight
Apr-01-19 Upgrade
KeyBanc Capital Markets
Sector Weight → Overweight
Apr-03-18 Upgrade
Raymond James
Mkt Perform → Outperform
Jan-05-18 Downgrade
Craig Hallum
Buy → Hold
Apr-07-17 Reiterated
Cantor Fitzgerald
Overweight
$20 → $21
Mar-30-17 Downgrade
KeyBanc Capital Mkts
Overweight → Sector Weight
Feb-08-17 Initiated
Barclays
Equal Weight
$17
Nov-04-16 Initiated
Cantor Fitzgerald
Buy
Apr-08-16 Resumed
Piper Jaffray
Neutral
Jan-08-16 Reiterated
Canaccord Genuity
Buy
$17.50 → $14.50
Nov-10-15 Downgrade
Raymond James
Outperform → Mkt Perform
Jul-24-15 Initiated
KeyBanc Capital Mkts
Overweight
Jun-19-14 Upgrade
Canaccord Genuity
Hold → Buy
$16.25 → $20
Oct-09-12 Reiterated
Canaccord Genuity
Hold
$14 → $13.50
Show Previous Ratings
Jul-07-25 08:00AM
Jun-26-25 10:55AM
08:23AM
Jun-24-25 10:43AM
Jun-23-25 08:00AM
11:40AM
Loading…
Jun-20-25 11:40AM
11:36AM
Jun-18-25 09:55AM
09:52AM
Jun-17-25 11:39AM
Jun-16-25 11:14AM
Jun-13-25 12:37PM
Jun-11-25 10:28AM
Jun-09-25 11:55AM
11:35AM
12:26PM
Loading…
Jun-06-25 12:26PM
09:41AM
Jun-05-25 12:07PM
Jun-04-25 12:31PM
12:26PM
12:00PM
Jun-03-25 12:10PM
Jun-02-25 08:38AM
May-30-25 10:14AM
09:40AM
May-29-25 10:08AM
10:06AM
09:31AM
May-28-25 11:50AM
11:47AM
09:22AM
Loading…
09:22AM
May-26-25 12:42PM
May-23-25 10:46AM
10:36AM
08:41AM
06:52AM
May-22-25 11:39AM
08:26AM
May-21-25 10:48AM
09:44AM
09:10AM
07:21AM
May-20-25 09:22AM
07:53AM
May-19-25 10:12AM
May-16-25 10:22AM
10:12AM
07:59AM
May-15-25 08:40AM
May-14-25 09:40AM
08:49AM
May-13-25 09:41AM
07:07AM
May-12-25 09:10AM
08:40AM
07:24AM
May-09-25 01:29PM
08:49AM
May-08-25 08:13AM
08:09AM
07:54AM
06:52AM
May-07-25 10:05AM
09:35AM
09:20AM
08:34AM
May-06-25 09:04AM
07:10AM
May-05-25 12:59PM
08:46AM
07:24AM
May-02-25 11:30AM
08:03AM
07:58AM
07:28AM
07:25AM
May-01-25 09:49AM
09:16AM
09:15AM
08:23AM
Apr-29-25 08:53AM
Apr-28-25 09:55AM
09:40AM
Apr-25-25 10:18AM
Apr-24-25 10:42AM
07:25AM
07:24AM
06:43AM
Apr-23-25 12:53PM
09:47AM
Apr-22-25 11:34AM
10:34AM
Apr-21-25 11:08AM
Apr-16-25 01:07PM
10:40AM
09:21AM
07:13AM
07:10AM
Apr-15-25 11:20AM
11:04AM
AngioDynamics, Inc. is a medical device company, which engages in the development, manufacturing, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage, thrombolytic, and venous products. It operates through the Med Tech and Med Device segments. The company was founded by Howard S. Stern and Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Nighan Warren JR SVP Quality and Regulatory Jan 16 '25 Sale 12.31 4,060 49,979 41,817 Jan 17 04:05 PM Nighan Warren JR Officer Jan 16 '25 Proposed Sale 12.31 4,060 49,979 Jan 16 04:05 PM Nighan Warren JR SVP Quality and Regulatory Oct 07 '24 Buy 6.09 768 4,677 45,777 Oct 10 03:22 PM Nighan Warren JR SVP Quality and Regulatory Oct 10 '24 Buy 6.08 100 608 45,877 Oct 10 03:22 PM Trowbridge Stephen A EVP and CFO Oct 08 '24 Buy 5.86 1,700 9,962 172,711 Oct 08 06:27 PM Clemmer James C President and CEO Oct 07 '24 Buy 6.03 20,000 120,600 681,582 Oct 08 04:32 PM Piccinini Laura SVP International Jul 17 '24 Option Exercise 0.00 4,439 0 42,491 Aug 02 09:55 PM Clemmer James C President and CEO Jul 17 '24 Option Exercise 0.00 56,279 0 690,312 Aug 02 09:53 PM Nighan Warren JR SVP Quality and Regulatory Jul 17 '24 Option Exercise 0.00 5,677 0 46,675 Aug 02 09:50 PM Campbell Chad Thomas SVP/GM, Vascular Access Jul 17 '24 Option Exercise 0.00 6,600 0 70,187 Aug 02 09:48 PM Trowbridge Stephen A EVP and CFO Jul 17 '24 Option Exercise 0.00 11,142 0 177,612 Aug 02 09:48 PM